<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Qi Y</submitter><pubmed_abstract>&lt;h4>Aim&lt;/h4>Chinese medicine Danhong injection (DHI) is an effective pharmaceutical preparation for treating cerebral infarction. Our previous study shows that DHI can remarkably reduce the ischemic stroke-induced infarct volume in a dose-dependent manner, but the pharmacological mechanism of the DHI dose-dependent relationship is not clear. Therefore, the dose-dependent efficacy of DHI on cerebral ischemia and the underlying mechanisms were further investigated in this study.&lt;h4>Methods&lt;/h4>A middle cerebral artery occlusion (MCAO) model was established and the rats were randomly divided into six groups: sham, vehicle, DHI dose-1, DHI dose-2, DHI dose-3, and DHI dose-4. Forty-one metabolites in serum were selected as candidate biomarkers of efficacy phenotypes by the Agilent 1290 rapid-re</pubmed_abstract><journal>Frontiers in neuroscience</journal><pagination>645185</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8439200</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Dose-Dependent Variation of Synchronous Metabolites and Modules in a Yin/Yang Transformation Model of Appointed Ischemia Metabolic Networks.</pubmed_title><pmcid>PMC8439200</pmcid><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Zhou N</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Zhu L</pubmed_authors><pubmed_authors>Qi Y</pubmed_authors><pubmed_authors>Jiang Q</pubmed_authors><pubmed_authors>Li B</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Xu W</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dose-Dependent Variation of Synchronous Metabolites and Modules in a Yin/Yang Transformation Model of Appointed Ischemia Metabolic Networks.</name><description>&lt;h4>Aim&lt;/h4>Chinese medicine Danhong injection (DHI) is an effective pharmaceutical preparation for treating cerebral infarction. Our previous study shows that DHI can remarkably reduce the ischemic stroke-induced infarct volume in a dose-dependent manner, but the pharmacological mechanism of the DHI dose-dependent relationship is not clear. Therefore, the dose-dependent efficacy of DHI on cerebral ischemia and the underlying mechanisms were further investigated in this study.&lt;h4>Methods&lt;/h4>A middle cerebral artery occlusion (MCAO) model was established and the rats were randomly divided into six groups: sham, vehicle, DHI dose-1, DHI dose-2, DHI dose-3, and DHI dose-4. Forty-one metabolites in serum were selected as candidate biomarkers of efficacy phenotypes by the Agilent 1290 rapid-re</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2026-05-09T04:41:06.615Z</modification><creation>2022-02-11T11:05:00.299Z</creation></dates><accession>S-EPMC8439200</accession><cross_references><pubmed>34531713</pubmed><doi>10.3389/fnins.2021.645185</doi></cross_references></HashMap>